s6y

Acumen Pharmaceuticals, Inc.

Ticker
ABOS
CIK
1576885
Industry
Biological Products, (No Diagnostic Substances)

Financials 22

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 22 financials filings

News 57

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 57 news filings

Ownership 156

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 156 ownership filings

Prospectus 25

  1. S-3 Registration statement for specified transactions by certain issuers
  2. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  5. S-3 Registration statement for specified transactions by certain issuers
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  10. S-3 Registration statement for specified transactions by certain issuers

All 25 prospectus filings

Proxies 11

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 11 proxies filings

Other 94

  1. EFFECT Notice of Effectiveness
  2. 144 Filing for proposed sale of securities under Rule 144
  3. 144 Filing for proposed sale of securities under Rule 144
  4. 144 Filing for proposed sale of securities under Rule 144
  5. 144 Filing for proposed sale of securities under Rule 144
  6. ARS Annual report to security holders
  7. SCHEDULE 13G
  8. EFFECT Notice of Effectiveness
  9. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  10. UPLOAD Letter (PDF)

All 94 other filings